- Co-founded Pharmetheus in 2012, actively working in client projects, leading the Business Development Team and the Communication & Marketing Team, and providing management support in Pharmetheus activities.
- Expertise includes model informed drug development, pharmacometrics (especially count data models, Markov models, and item response theory models), and trial design in therapeutic areas such as neuroscience, women’s health, and immunology.
- Experience as Researcher at Uppsala University, where she has a part-time position to perform pharmacometric research, primarily by supervision of Postdoctoral Researchers. Previously, she worked as deputy CEO and Project Portfolio Team Leader at Pharmetheus, Sweden, and Visiting Scientist at Metrum Research Group, USA.
- M.Sc. in Biostatistics (2006) from University Paris Diderot, France, Pharm.D. (2007) from University of Poitiers, France, and Ph.D. in Pharmaceutical Biosciences (2011) from Uppsala University, Sweden.
Pharmetheus affiliated publications
Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357 treatmentA disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo scoreTraining the next generation of pharmacometric modelers: a multisector perspectiveBounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357Enhancing Efficiency and Decision Quality in Parkinson’s Disease Drug Trials for LRRK2 Programs Using Item Response ModellingModel Based Support to Biosimilarity Assessment Planning – A Case Study of PegfilgrastimSensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity StudiesAssessment of Expected Drug Exposure Relative Maximum Safety Limits in Early Phase StudiesA Population Pharmacokinetic-Pharmacodynamic Model of PegfilgrastimDosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial DataModel Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics